Fig. 1
From: Application of imiquimod-induced murine psoriasis model in evaluating interleukin-17A antagonist
Optimization of Imiquimod (IMQ)-induced Psoriasis Model for Exhibiting Efficacy of Interleukin-17A Antibody on C57BL/6 Mice. a Skin damage (on day 5 of experiment) and b disease severity of 62.5 mg IMQ induced-psoriasis in mice. c Protective effect of Dexamethasone (10 mg/kg, daily) on 62.5 mg IMQ-induced psoriasis in mice. Effect of IMQ in different dosages on d disease severity and e bodyweight of mice. f Protective effect of Anti-IL17A antibody in different dosages (0.1–1 mg/kg) on IMQ (42 mg) induced psoriasis. “PASI Score” plot indicated disease severity evaluated by Psoriasis Area Severity Index (PASI) system (n = 6). Data was expressed as mean ± SEM, Anti-IL17A, Anti-IL17A antibody; Dex, Dexamethasone